Pemivibart Is Well Tolerated, Demonstrates Prophylactic Efficacy Against Symptomatic COVID-19 Infection, Study Finds

Infectious Disease Advisor (7/29, Basilio) reports, “The long-acting monoclonal antibody pemivibart is generally well tolerated and demonstrates prophylactic efficacy against symptomatic COVID-19 infection, according to study findings.” Interim data “from a phase 3 trial suggest pemivibart may be effective prophylaxis against COVID-19 infection for high-risk patients with significant immunocompromising conditions who continue to have suboptimal vaccine response.” The findings were published in Clinical Infectious Diseases.